8th Sep 2026 07:00
Diaceutics - Notice of Results & Presentations
New York, Belfast and London, 8 September 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, will announce its unaudited results for the half year ended 30 June 2026 on Tuesday, 22 September 2026.
Analyst Presentation:
A webinar presentation for analysts and investors will be held at 1400 BST (0900 EDT) on Tuesday, 22 September 2026. Those wishing to attend can register their interest using the following link:
https://us06web.zoom.us/webinar/register/WN_UrTI-vTlSKWPJJwd7_9KlA
Enquiries:
Diaceutics PLC | |
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer | Tel: +44 (0)28 9040 6500
|
Canaccord Genuity Limited (Nomad & Broker) | Tel: +44 (0)20 7523 8000 |
Simon Bridges, Andrew Potts, Harry Rees |
About Diaceutics
At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.
Related Shares:
Diaceutics